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Zusammenfassung
Hintergrund: Patienten mit Mantelzellymphomen haben
auch heute eine schlechte Prognose, insbesondere bei
Befall des ZNS. Um eine bestehende Meningeosis lym-
phomatosa zu sichern ist die Gewinnung von Liquor not-
wendig, wobei bei klinischer Evidenz unmittelbar an-
schließend eine intrathekale Therapie verabreicht wer-
den kann. Ist dies durch Lumbalpunktion z. B. aufgrund
eines lumbalen Befalles nicht möglich, so kann alternativ
der Zugang über eine laterale subokzipitale Punktion ge-
wählt werden. Patient und Methoden: Wir berichten über
einen 65 Jahre alten Patienten mit Mantelzellymphom
Stadium IV, der mit einer progredienten Paraparese bei-
der Beine sowie Harn- und Stuhlinkontinenz bei intradu-
ralen Tumormassen von BWK 12 bis SWK 1 ins Kranken-
haus eingewiesen wurde. Während der Bestrahlung im
Wirbelsäulenbereich entwickelte der Patient Symptome
einer diffusen Meningeosis lymphomatosa. Eine konven-
tionelle Lumbalpunktion erschien aufgrund des intradu-
ralen Tumors im Bereich der LWS nicht durchführbar. Er-
gebnisse: Diagnostik und Therapie wurden über eine di-
rekte subokzipitale Punktion durchgeführt, bei der Liquor
gewonnen und anschließend eine intrathekale Chemo-
therapie (Cytosinarabinosid/Dexamethason) verabreicht
wurde. Daraufhin besserte sich der klinische Zustand des
Patienten rasch. Schlussfolgerung: Die laterale subokzi-
pitale Liquorpunktion und Instillation von Chemothera-
pie erwies sich in diesem Fall, in dem eine lumbale Li-
quorpunktion nicht möglich war, als komplikationslos
und erfolgreich durchführbar und kann in ähnlichen Fäl-
len als Alternative dienen.
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Summary
Background: Even today patients who suffer from mantle
cell lymphoma have a poor prognosis, especially when
the CNS is involved. To confirm the diagnosis of menin-
geosis lymphomatosa, asservation of the liquor cerebro-
spinalis is necessary. During this procedure, intrathecal
chemotherapy may be given if there is clinical evidence
of meningeosis. If lumbar puncture cannot be perfor-
med, a lateral suboccipital puncture may be an alternati-
ve approach. Patient and Methods: We report the case of
a 65-year-old patient who suffered from mantle cell lym-
phoma stage IV. The patient presented with symptoms of
progressive paraparesis of both legs and incontinence,
with tumor mass intradural from the 12th thoracic verte-
bra to the level of S1. During irradiation, the patient de-
veloped symptoms of diffuse meningiosis lymphomato-
sa. The conventional lumbar puncture was impossible,
because of tumor present in the thoracico-lumbar junc-
tion. Results: A suboccipital puncture was performed for
both collecting cerebrospinal fluid and application of
chemotherapy (cytosine arabinoside/dexamethasone).
This lead to remarkable improvement of the patient’s cli-
nical symptoms. Conclusion: The suboccipital cervical
puncture was performed without complications. A varia-
tion of the intrathecal approach is described, which may
serve as alternative when conventional lumbar puncture
is not possible.
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Introduction
Mantle cell lymphoma (MCL) is a subtype of non-Hodgin’s
lymphoma (NHL) that often presents in advanced stages with
systemic spread [1]. Spinal involvement is uncommon and
generally occurs as part of advanced disease or generalized re-
lapses. Primary spinal epidural lymphoma is a rare initial man-
ifestation, and mantle cell lymphoma with initial presentation
in the spinal epidural space is extremely rare [1]. MCL is con-
sidered a distinct disease entity within the heterogenous group
of NHL, although the cytology and growth pattern of MCL
can be quite variable and the clinical significance of these fea-
tures is unclear. 
MCL was classified in the past (Kiel classification) as centro-
cytic lymphoma [2], lymphocytic lymphoma of intermediate
differentiation (1974) and mantle cell lymphoma (1982); in the
working formulation it was considered as either small lympho-
cytic lymphoma, follicular small cleaved cell lymphoma, or
diffuse large cleaved cell lymphoma [3]. Specific diagnostic
criteria, based on morphologic, cytogenetic and immunophe-
notypic features, have been proposed in REAL and WHO
classifications (in 1994 and 1999, respectively), which suggest-
ed that MCL should be regarded as a specific entity. 
MCL cells are derived from the follicle mantle of lymph
nodes, physiologically representing 2–5% of normal B cells in
adult lymph nodes and tonsils. A characteristic cytogenetic ab-
normality, the t(11;14)(q13;q32) can be detected in about 75%
of patients [2]. A deleted segment of 11q22-q23 bands affect-
ing the ATM (ataxia-teleangiectasia mutated) gene in 50% of
MCL has recently been identified; extinction of ATM func-
tion might be the first event leading to malignant transforma-
tion of cells of the follicular mantle. Other abnormalities such
as p53 mutations, inactivation of the CDKN2/p16 gene or
overexpression of the c-myc gene are observed in 5–38% of
the patients and usually associated with unfavorable prognosis
[3].
The incidence of MCL is 3 in 100,000 residents [4]. In Europe,
7–9% of the patients with NHL suffer from MCL [5]. There is
a predominance of male patients with a male/female ratio >6.
B symptoms are reported in 25–50% of the patients; multiple
gastrointestinal involvement is reported in 15–40% and bone
marrow infiltration is detected in 60%. 
About 80–90% of newly diagnosed patients are stage III–IV
according to the Ann Arbor classification [3]. MCL has a poor
prognosis; median survival time is 3–4 years. Main prognostic
criteria are presence of large blastoid cells, age > 60 years,
stage II–IV, elevated LDH level and circulating lymphoma
cells.
The diagnosis of MCL, especially of high grade variants, is
particularly challenging, as these tumors exhibit a broad spec-
trum of morphologic findings that can be misinterpreted as
other types of NHL [5]. Histologic review includes study of
the morphological appearance of the cells and architectural
pattern, immunohistochemical analysis using the monoclonal
antibodies CD3, CD5, CD10, CD19, CD20, CD23, heavy- and
light-chain immunoglobulins and description of cytogenetic
abnormalities according to the International System for
Human Cytogenetic Nomenclature [3].
The treatment of MCL depends on the tumor stage. Stage I–II
are treated with radiation therapy with 26–40 Gy [2]. Stage
III–IV are treated with various chemotherapy regimens; stud-
ies showed better response rates of anthracyclin-based regi-
mens, however, without any impact on the natural history of
the disease and on survival compared to other chemotherapy
regimens. Other substances, such as fludarabin, paclitaxel, and
gemcitabine have been tested with response rates between 14
and 33%. Combinations of 2CDA (2-chlordeoxyadenosine)
and mitoxantrone achieved 3% complete remissions and
100% responses, the median duration of response varied be-
tween 18 and 24 months [3].
High-dose chemotherapy in combination with autologous
stem cell transplantation is being investigated. Complete re-
mission rates varied between 44 and 100% in various non-ran-
domized studies; despite improved median survival most stud-
ies showed no evidence for long-term remission [3].
The effect of monoclonal anti-CD20 antibody (rituximab) is
now being evaluated in various studies. Recent approaches
have tested in vivo purging of blood and bone marrow with
rituximab and subsequent stem cell transplantation with en-
couraging results so far (26/28 patients disease-free after a me-
dian follow-up of 22 months; 2 patients died) [6].
Involvement of the central nervous system is a rare complica-
tion in patients with mantle cell lymphoma. Oinonen et al. [7]
retrospectively analyzed 94 patients with histologically con-
firmed MCL and found CNS involvement in 4 patients (4%).
CNS involvement occurred 4.6–86 months after first diagnosis.
All patients had neurological symptoms and leukemic disease;
in 2 cases blastoid transformation was suspected. Malignant
cells were detected in the cerebrospinal fluid in all cases,
parenchymal infiltrations in the brain were seen in 2 cases. All
patients were treated with intrathecal chemotherapy without
response; survival time after diagnosis ranged from 18 to 55
days. Another study of Valdez et al. [8] reviewed the medical
records of 108 patients with MCL for CNS involvement; the
overall rate of positive cytologic findings in the cerebrospinal
fluid being 9%.
The diagnosis of meningeal manifestations can be based on
clinical symptoms, lumbar puncture and magnetic resonance
imaging (MRI). With the aid of MRI, it has been possible to
obtain direct images of neoplastic meningeosis [9]. However,
the microscopic analysis of cells in the cerebrospinal fluid still
remains essential.
We here report the case of a patient with pseudoobstruction of
the spinal channel due to an intradural mass. Therefore, the
classical way of performing a lumbar puncture was not advis-
able. In his case, also meningeal enhancement detected by cra-
nial MRI indicated that an external ventricular drainage
would not be sufficient.
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The diagnostic/therapeutic procedures in those cases are limit-
ed to suboccipital puncture. Originally there were numerous
diagnostic, therapeutic and scientific indications for suboccipi-
tal puncture. Most of them are out of date [10]. Still, it is a
practicable alternative when lumbar puncture is impossible.
The application of the suboccipital puncture procedure for in-
jection of intrathecal chemotherapy will be described in this
case report. 
Patient and Methods
The patient was a 65-year-old male who suffered from stage IV MCL
since July 2000. Mainly involved organs were the small bowel and ileum.
He initially presented with symptoms of acute abdomen. Partial small
bowel resection was performed. The histologic findings showed infiltrati-
on by MCL. Between August and December 2000, he was treated with 6
cycles of COP (cyclophosphamide, vincristine, and prednisone) chemo-
therapy, with partial remission. From January till May 2001, he was given
8 cycles of CHOP (COP+ adriamycin) with complete remission, confir-
med by computer tomography scanning. 
At the end of July 2001, acute progressive paraparesis of both legs and in-
continence occurred. MRI showed intradural tumor masses from the 12th
thoracic vertebra to the level of S1. Further manifestations of the disease
were massive intra-abdominal bulk and lymphadenopathy in the right
axillary region as well as in the region of hilus and the carina. Biopsy of
the axillary lymph nodes confirmed the recurrence of anaplastic MCL. In
this palliative situation with quick progression of symptoms we decided to
proceed with irradiation of the spinal cord from TH11 to S1, with the aim
of reducing the tumor mass in this region to try to avoid irreversible para-
paresis and incontinence. The irradiation was performed using a 6 MV li-
near accelerator, with application of 20.0 Gy (2.0 Gy per session). Initially
the patient showed significant improvement of the neurological sym-
ptoms. 
After 10 days of treatment the patient reported headache. He was partial-
ly desoriented with respect to time and place. Physical examinations sho-
wed nuchal hardness and partial blindness and deafness. MRI confirmed
the suspected meningeosis lymphomatosa.
A conventional lumbar puncture was not performed because of the tumor
being present in Th12–S1. We decided to proceed with suboccipital punc-
ture to achieve two simultanous aims: diagnostic (tumor cells in the cere-
brospinal fluid above the level of the obstruction) and therapeutic ap-
proach by giving intrathecal chemotherapy (cytosine arabinoside (Ara-C)
and dexamethasone).
For suboccipital puncture procedure, the patient was positioned with ex-
tended neck in prone position on a fluoroscopic x-ray device. Guided by
strict lateral fluoroscopic x-ray-beam a long 21 G needle was inserted
under sterile conditions and under local (lateral) anesthesia. After lateral
puncture of the skin just caudal the ear, the needle was aimed at the line
between the anterior surface of the dorsal arches of C1 and C2 and under
strict fluoroscopic control advanced to the midline. When the needle tip
was advanced, the beam of fluoroscopy was altered from lateral to anteri-
or-posterior and vice versa, as the lateral view best controls the direction
of the needle advancement and the anterior-posterior view enables to mo-
nitor the advancement of the needle tip to the midline. Following this ap-
proach, the needle reached the cisterna cerebro-medullaris. The flow of
clear spinal fluid indicated a correct position, which was verified by x-ray
and contrast injection (fig. 1).
Results
The suboccipital puncture procedure was performed without
complications. The obtained cerebrospinal fluid contained
2944/3 cells (identified as lymphoma cells) and few red blood
cells. Also the intrathecal injection of 40 mg Ara-C and 8 mg
Dexamethasone proceeded without any complications. Under
this regimen, the patient showed improvement of the clinical
symptoms, especially improvement of orientation, headache
and partial recovery of blindness and loss of hearing within a
few hours. 
The diagnostic confirmation lead us to implant an Ommaya
reservoir for further intrathecal chemotherapy [11]. This lead
to a partial remission with no remarkable side effects. After
two weeks, the patient received systemic chemotherapy. He
died a few days later because of systemic organ failure, possi-
bly due to infection during neutropenia.
Conclusions
We here described an alternative approach for spinal injec-
tion of chemotherapeutic agents in a patient with epidural
masses caused by mantle-cell lymphoma. Due to the localiza-
tion of these masses a lumbar approach was not possible in
this patient. Thus, we decided to perform a suboccipital
puncture. 
The suboccipital puncture today is a rare procedure [10], still
it is a practicable alternative when lumbar puncture is impos-
sible. The lateral cervical suboccipital puncture offers an alter-
native for diagnostic and therapeutic approaches. The extra-
cranial part of the cisterna magna cerebellomedullaris pro-
vides enough space to ensure the definite position of the nee-
dle without any major risk after puncture through the
atlanto-occipital membrane. Complications of this approach
can include problems related to the hyperextension of the cer-
vical spinal canal, so care should be taken to exclude patients
with a narrow spinal canal [12]. We did not observe, as report-
ed in the past [13, 14], side effects such as pharyngeal pain or
Lhermitte’s sign. Other rare complications include puncture
of the vertebral arteries [15]. Alternatively, an intrathecal ad-
ministration of chemotherapeutic agents can also be per-
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Fig. 1. Schematic representation of the suboccipital puncture procedure.
A) Transverse section. B) Sagittal section.
formed by an external ventricular drainage through an Om-
maya reservoir [11]. Positioning of the needle tip is possible
under simple x-ray control. Injury of the spinal cord is most
unlikely to occur.
Pharmacokinetic studies have indicated that a potentially ef-
fective concentration of Ara-C is reached in cerebrospinal
fluid during and after high-dose infusions of the drug given in-
travenously. The proven effectivity of intrathecal treatment in
patients with meningeosis lymphomatosa [16, 17] lead us to
use these agents. Methotrexate (MTX) can also be used for in-
trathecal treatment [18].
The partial remission achieved in this patient confirms the fea-
sibility of this approach in rare cases like the case reported
here.
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